JP5719783B2 - アポリポタンパクａ−ｉ模倣物 - Google Patents

アポリポタンパクａ−ｉ模倣物 Download PDF

Info

Publication number
JP5719783B2
JP5719783B2 JP2011550271A JP2011550271A JP5719783B2 JP 5719783 B2 JP5719783 B2 JP 5719783B2 JP 2011550271 A JP2011550271 A JP 2011550271A JP 2011550271 A JP2011550271 A JP 2011550271A JP 5719783 B2 JP5719783 B2 JP 5719783B2
Authority
JP
Japan
Prior art keywords
leu
peptide
amino acid
glu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011550271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012518006A (ja
JP2012518006A5 (enExample
Inventor
ダシュー，ジーン−ルイス
シュウェンドマン，アンナ，シェンダーロヴァ
ジュ，リンユ
Original Assignee
セレニス セラピューティクス ホールディング エスアー
セレニス セラピューティクス ホールディング エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレニス セラピューティクス ホールディング エスアー, セレニス セラピューティクス ホールディング エスアー filed Critical セレニス セラピューティクス ホールディング エスアー
Publication of JP2012518006A publication Critical patent/JP2012518006A/ja
Publication of JP2012518006A5 publication Critical patent/JP2012518006A5/ja
Application granted granted Critical
Publication of JP5719783B2 publication Critical patent/JP5719783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
JP2011550271A 2009-02-16 2010-02-12 アポリポタンパクａ−ｉ模倣物 Active JP5719783B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US15296009P 2009-02-16 2009-02-16
US15296609P 2009-02-16 2009-02-16
US15296209P 2009-02-16 2009-02-16
US61/152,960 2009-02-16
US61/152,962 2009-02-16
US61/152,966 2009-02-16
PCT/US2010/024096 WO2010093918A1 (en) 2009-02-16 2010-02-12 Apolipoprotein a-i mimics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015058887A Division JP2015110677A (ja) 2009-02-16 2015-03-23 アポリポタンパクａ−ｉ模倣物

Publications (3)

Publication Number Publication Date
JP2012518006A JP2012518006A (ja) 2012-08-09
JP2012518006A5 JP2012518006A5 (enExample) 2012-11-15
JP5719783B2 true JP5719783B2 (ja) 2015-05-20

Family

ID=42562076

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011550271A Active JP5719783B2 (ja) 2009-02-16 2010-02-12 アポリポタンパクａ−ｉ模倣物
JP2015058887A Pending JP2015110677A (ja) 2009-02-16 2015-03-23 アポリポタンパクａ−ｉ模倣物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015058887A Pending JP2015110677A (ja) 2009-02-16 2015-03-23 アポリポタンパクａ−ｉ模倣物

Country Status (26)

Country Link
US (4) US8378068B2 (enExample)
EP (2) EP2939683B1 (enExample)
JP (2) JP5719783B2 (enExample)
KR (1) KR101688547B1 (enExample)
CN (2) CN102395375B (enExample)
AU (1) AU2010213568B2 (enExample)
CA (2) CA2982157A1 (enExample)
CY (1) CY1118809T1 (enExample)
DK (2) DK2396017T3 (enExample)
ES (2) ES2620478T3 (enExample)
HK (1) HK1209436A1 (enExample)
HR (2) HRP20150998T1 (enExample)
HU (2) HUE026062T2 (enExample)
IL (2) IL214576B (enExample)
LT (1) LT2939683T (enExample)
MX (3) MX343654B (enExample)
NZ (1) NZ594516A (enExample)
PH (1) PH12016501912A1 (enExample)
PL (2) PL2396017T3 (enExample)
PT (2) PT2939683T (enExample)
RU (2) RU2532222C2 (enExample)
SG (1) SG173624A1 (enExample)
SI (2) SI2939683T1 (enExample)
SM (2) SMT201700203T1 (enExample)
WO (1) WO2010093918A1 (enExample)
ZA (1) ZA201105997B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
US20120141576A1 (en) * 2007-03-15 2012-06-07 Benjamin Johnson Treatment of Dermatologic Skin Disorders
WO2008141230A1 (en) 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
US9688718B2 (en) 2008-01-11 2017-06-27 Lawrence Livermore National Security, Llc Nanolipoprotein particles comprising hydrogenases and related products, methods and systems
DK2396017T3 (en) 2009-02-16 2015-09-14 Cerenis Therapeutics Holding Sa Apolipoprotein A-I-mimetika
ES2648788T3 (es) 2011-01-26 2018-01-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
AU2015271986B2 (en) * 2011-02-07 2018-02-22 Cerenis Therapeutics Holding Sa Lipoprotein complexes and manufacturing and uses thereof
US9644038B2 (en) 2011-12-21 2017-05-09 The Regents Of The University Of California Apolipoprotein nanodiscs with telodendrimer
WO2013188879A1 (en) 2012-06-16 2013-12-19 Atherotech, Inc. Measurement of serum lipoproteins
US9239280B2 (en) * 2012-06-16 2016-01-19 Atherotech, Inc. Measurement of serum lipoproteins
MX2016014306A (es) 2014-05-02 2017-06-12 Cerenis Therapeutics Holding Sa Marcadores para terapia con lipoproteinas de alta densidad (hdl).
WO2016049061A1 (en) 2014-09-22 2016-03-31 Lawrence Livermore National Security, Llc Electrochemical flow-cell for hydrogen production and nicotinamide co-factor dependent target reduction, and related methods and systems
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2017035326A1 (en) 2015-08-25 2017-03-02 Lawrence Livermore National Security, Llc Stable nanolipoprotein particles and related compositions methods and systems
WO2017044899A1 (en) * 2015-09-11 2017-03-16 Lawrence Livermore National Security, Llc Synthetic apolipoproteins, and related compositions methods and systems for nanolipoprotein particles formation
US20190201540A1 (en) * 2016-05-24 2019-07-04 Stc Unm Immunogens, compositions, and methods for treating dyslipidemia
US12083223B2 (en) 2017-05-02 2024-09-10 Lawrence Livermore National Security, Llc Nanolipoprotein particles and related compositions methods and systems for loading RNA
WO2018204421A2 (en) 2017-05-02 2018-11-08 Lawrence Livermore National Security, Llc Momp telonanoparticles, and related compositions, methods and systems
TW201919686A (zh) * 2017-08-10 2019-06-01 法商塞勒尼斯醫療控股公司 脫輔基子(apomers)
WO2019030574A1 (en) * 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2021209808A1 (en) * 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
CN115666720A (zh) 2020-04-16 2023-01-31 阿比奥尼克斯制药公司 用于治疗肾病的cer-001疗法
EP4135747A1 (en) 2020-04-16 2023-02-22 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein- based complexes
JP2023543498A (ja) 2020-10-01 2023-10-16 アビオニクス ファーマ エスエー 脂質結合タンパク質ベースの複合体を使用した、眼疾患を治療するための方法
EP4259280A4 (en) * 2020-12-11 2025-02-12 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles
JP2024514154A (ja) 2021-04-15 2024-03-28 アビオニクス ファーマ エスエー 臓器保存溶液における脂質結合タンパク質ベースの複合体の使用
CN114940711B (zh) * 2021-10-25 2023-05-12 中山大学 载脂蛋白a-i模拟肽及其应用
EP4504150A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating eye diseases using lipid binding protein-based complexes
EP4504233A1 (en) 2022-04-06 2025-02-12 Abionyx Pharma SA Methods for treating leukocytosis, endothelial dysfunction and carditis using lipid binding protein-based complexes
CN120344255A (zh) 2022-06-10 2025-07-18 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗过度炎性病症的方法
EP4536269A2 (en) 2022-06-10 2025-04-16 Abionyx Pharma SA Methods for treating acute conditions using lipid binding protein-based complexes
US12060148B2 (en) 2022-08-16 2024-08-13 Honeywell International Inc. Ground resonance detection and warning system and method
AU2024207875A1 (en) 2023-01-13 2025-07-24 Abionyx Pharma Sa Lipid binding protein molecule therapy
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (enExample) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) * 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
JPS61152632A (ja) 1984-12-26 1986-07-11 Dai Ichi Seiyaku Co Ltd 抗動脈硬化剤
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
JPH0559081A (ja) 1991-08-29 1993-03-09 Kirin Brewery Co Ltd 新規スフインゴ糖脂質、その製造法および使用
WO1993025581A1 (en) 1992-06-12 1993-12-23 N.V. Innogenetics S.A. New peptides and proteins, process for their preparation and their use as cholesterol acceptors
TW261533B (enExample) 1992-07-16 1995-11-01 Kirin Brewery
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
CA2143848C (en) 1992-10-01 2007-09-11 W. Clark Still Complex combinatorial chemical libraries encoded with tags
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU765809B2 (en) 1998-02-12 2003-10-02 Emory University Sphingolipid derivatives and their methods of use
CN1329359C (zh) 1999-04-01 2007-08-01 埃斯佩里安医疗公司 醚化合物,及其组合物和用途
PT1290013E (pt) * 2000-04-21 2006-06-30 Amgen Inc Derivados dos peptidos apo-ai/aii
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
CA2460787A1 (en) 2001-09-28 2003-04-03 Esperion Therapeutics, Inc. Prevention and treatment of restenosis by local administration of drug
BR0310099A (pt) * 2002-05-17 2007-03-20 Esperion Therapeutics Inc método para tratar dislipidemia ou uma doença associada com a dislipidemia
DE10237571A1 (de) 2002-08-13 2004-02-26 Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin Endovaskuläres Implantat mit aktiver Beschichtung
AU2004252174A1 (en) 2003-06-26 2005-01-06 Migenix Inc. Compositions of lipopeptide antibiotic derivatives and methods of use thereof
BRPI0513402A (pt) * 2004-07-16 2008-05-06 Tufts College miméticos de apolipoproteìna a1 e usos dos mesmos
US8206750B2 (en) * 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
JP2008542685A (ja) 2005-05-05 2008-11-27 ヴァロリザーシヨン・アッシュエスジ，ソシエテ・アン・コマンディット サイトカイン受容体修飾因子及びその使用
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
US8163699B2 (en) * 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
US20080138284A1 (en) * 2006-09-26 2008-06-12 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2008094905A2 (en) 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
US7956035B2 (en) 2007-03-01 2011-06-07 Csl Limited Treatment of endothelial dysfunction in diabetic patients
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2010083611A1 (en) 2009-01-23 2010-07-29 Institut De Cardiologie De Montreal Method for the prevention and treatment of diastolic dysfunction employing an apolipoproteina1 (apoa1) mimetic peptide/phospholipid complex
DK2396017T3 (en) 2009-02-16 2015-09-14 Cerenis Therapeutics Holding Sa Apolipoprotein A-I-mimetika
US20130197226A1 (en) * 2010-07-28 2013-08-01 Jean-Claude Tardif Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
CN105051051B (zh) 2013-03-15 2021-07-16 萨瑞斯治疗控股公司 用于合成神经鞘磷脂和二氢神经鞘磷脂的方法
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins

Also Published As

Publication number Publication date
ZA201105997B (en) 2013-10-30
MX386110B (es) 2025-03-18
CN102395375B (zh) 2015-01-14
HUE033661T2 (en) 2017-12-28
HK1209436A1 (en) 2016-04-01
ES2554853T3 (es) 2015-12-23
AU2010213568B2 (en) 2014-11-20
HUE026062T2 (en) 2016-05-30
PH12016501912A1 (en) 2019-11-18
PT2396017E (pt) 2015-10-22
US20130231459A1 (en) 2013-09-05
SMT201700203T1 (it) 2017-05-08
AU2010213568A1 (en) 2011-09-01
HRP20170294T1 (hr) 2017-04-21
JP2012518006A (ja) 2012-08-09
JP2015110677A (ja) 2015-06-18
US20100267631A1 (en) 2010-10-21
SI2939683T1 (sl) 2017-04-26
PL2939683T3 (pl) 2017-07-31
SI2396017T1 (sl) 2015-12-31
IL240357A (en) 2017-11-30
CA2982157A1 (en) 2010-08-19
US20150141330A1 (en) 2015-05-21
CN102395375A (zh) 2012-03-28
IL240357A0 (en) 2015-09-24
HK1165987A1 (en) 2012-10-19
EP2939683A1 (en) 2015-11-04
RU2532222C2 (ru) 2014-10-27
RU2014134333A (ru) 2016-03-20
LT2939683T (lt) 2017-03-27
CY1118809T1 (el) 2018-01-10
MX343654B (es) 2016-11-16
CN104530223A (zh) 2015-04-22
EP2396017A4 (en) 2013-03-27
PL2396017T3 (pl) 2015-12-31
PT2939683T (pt) 2017-04-07
SMT201500318B (it) 2016-02-25
KR20120004412A (ko) 2012-01-12
SG173624A1 (en) 2011-09-29
EP2396017B1 (en) 2015-07-01
US8993597B2 (en) 2015-03-31
KR101688547B1 (ko) 2016-12-21
CA2752182C (en) 2017-11-28
MX2011008599A (es) 2011-11-18
US9388232B2 (en) 2016-07-12
CA2752182A1 (en) 2010-08-19
NZ594516A (en) 2012-12-21
RU2011138011A (ru) 2013-03-27
US9981008B2 (en) 2018-05-29
EP2939683B1 (en) 2017-01-04
HRP20150998T1 (hr) 2015-11-20
WO2010093918A1 (en) 2010-08-19
ES2620478T3 (es) 2017-06-28
DK2396017T3 (en) 2015-09-14
IL214576A0 (en) 2011-09-27
EP2396017A1 (en) 2011-12-21
US20160324923A1 (en) 2016-11-10
DK2939683T3 (en) 2017-03-13
US8378068B2 (en) 2013-02-19
IL214576B (en) 2019-05-30

Similar Documents

Publication Publication Date Title
JP5719783B2 (ja) アポリポタンパクａ−ｉ模倣物
AU2005201985B2 (en) Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
KR100650974B1 (ko) 비정상 지혈증 장애 치료용 아포리포단백질 ａ-ｉ 유사 펩티드
AU2002300464C1 (en) Apoliprotein A-I Agonist And Their Use To Treat Dyslipidemic Disorders
AU2014268255B2 (en) Apolipoprotein a-i mimics
HK1165987B (en) Apolipoprotein a-i mimics

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20120806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140508

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140808

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150223

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150323

R150 Certificate of patent or registration of utility model

Ref document number: 5719783

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250